Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by noodleyon Oct 11, 2010 7:02pm
386 Views
Post# 17552195

RE: RE: RE: Meeting with FDS

RE: RE: RE: Meeting with FDSit's actually mon, 20 dec.  the process will take a few weeks...so don't expect yeah or nay till late january.  nobody's dead and the hotsauce looks like it works.  fda is not gonna shut these guys down.  but while the share price might jump to mid/upper teens with an fda thumbs up.....a partner willing to invest 30-40 million is required for phase 3.  tall order.  that's really what we're waiting for, isn't it?   
Bullboard Posts